Often viewed as merely an inconsequential episode of acute joint pain, gout flare has also been associated with an increased risk of acute myocardial infarction and stroke. New findings suggest the risk is highest within the first 60 days of gout flare, and could be influenced by flare treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Choi, H. K., McCormick, N. & Yokose, C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat. Rev. Rheumatol. 18, 97–111 (2022).
Cipolletta, E. et al. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 328, 440–450 (2022).
Perez-Ruiz, F. et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann. Rheum. Dis. 73, 177–182 (2013).
Choi, H. K., Neogi, T., Stamp, L. K., Terkeltaub, R. & Dalbeth, N. Reassessing the cardiovascular safety of febuxostat: implications of the Febuxostat versus Allopurinol Streamlined Trial. Arthritis Rheumatol. 73, 721–724 (2021).
Kwong, J. C., Schwartz, K. L. & Campitelli, M. A. Acute myocardial infarction after laboratory-confirmed influenza infection. N. Engl. J. Med. 378, 2540–2541 (2018).
Smeeth, L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351, 2611–2618 (2004).
Yokose, C., McCormick, N. & Choi, H. K. The role of diet in hyperuricemia and gout. Curr. Opin. Rheumatol. 33, 135–144 (2021).
Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
Choi, H. K., Zhang, Y. & Dalbeth, N. When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy. Nat. Rev. Rheumatol. 18, 543–549 (2022).
Saag, K. G., Becker, M. A. & White, W. B. Evaluation of the relationship between serum urate levels, clinical manifestations of gout, and death from cardiovascular causes in patients receiving febuxostat or allopurinol in an outcomes trial. Arthritis Rheumatol. 74, 1593–1601 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.K.C. declares receipt of research support from Horizon, and consulting fees from Allena, Protalix, and LG Chem. N.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Choi, H.K., McCormick, N. Beyond joint pain, could each gout flare lead to heart attack?. Nat Rev Rheumatol 18, 619–620 (2022). https://doi.org/10.1038/s41584-022-00844-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-022-00844-x
This article is cited by
-
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Nature Reviews Rheumatology (2024)